(NASDQ: $RGC ) #RGCgivingback - Anyone, Anywhere, You Can Make A Difference! rgcfoundation.org

https://www.dropbox.com/scl/fi/5giusloz22bsl5zax1go6/RGCgivingback-Anyone-Anywhere-You-Can-Make-A-Difference-rgcfoundation.org-2023.docx?dl=0&rlkey=f4alsbg6ehuppb39w029y4u7e

$RGC - 81% of Regencell Bioscience Holdings Limited (NASDAQ:RGC) is owned by insiders, and they've been buying recently

https://finance.yahoo.com/news/81-regencell-bioscience-holdings-limited-105517095.html

Pretty $olid

$RGC Regencell Bioscience: Transforming Patient Treatment with Innovative Biotech Solutions
The CEO of Regencell, Yat-Gai Au, has expressed his goal and vision for the future of the company, with the aim of transforming the way patients are treated. Despite the current financial difficulties faced by the market and economy, Regencell is poised to lead the charge in the biotech and bioscience industry, which has seen a significant influx of investments in recent times.

The past few months have been a trying time for investors, as the ongoing health crisis and political unrest have taken a toll on market and economic performance. The Federal Reserve's decision to raise interest rates and the nation's spiraling inflation, which has reached a 40-year high, has only added to the uncertainty and instability.

However, there are industries that are trying to attract investors with innovative strategies, as businesses aim to increase their impact and market domination. The biotech and bioscience industry is one such example, with many investors willing to take a chance on some of the shares in their portfolio to mitigate the effects of a potential recession.

A McKinsey research report from 2022 showed that biotech companies raised more than $34 billion globally in 2021, a significant increase from the $16 billion raised in 2020. This trend is further reflected in the continuous investment in therapeutic-based biotech startups by venture capital companies, which amounted to more than $52 billion between 2019 and 2021, even during the height of the pandemic.

Yat-Gai Au, who is the founder and CEO of Regencell Bioscience, has been taking a proactive approach to securing the future of the company. He has made purchases of ordinary company shares from the open market since Regencell was listed on NASDAQ in mid-July 2021. This move is aimed at dealing with the short and disrupted investing schemes used on the company's stocks, which can have a negative impact on overall stock performance if left unchecked.

The CEO's commitment to the future of Regencell is evident, as he has invested millions of his personal funds to purchase company shares. He is fully devoted to his plan and the future of the company, which is poised to make a major impact in the biotech and bioscience industry. With Regencell's cutting-edge research and development in the field of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and infectious diseases, the company is well positioned to change the way patients are treated and improve lives.

For more information about Regencell Bioscience and their work, visit their website at www.regencellbioscience.com and stay updated on their latest developments.

Revolutionizing ADHD and ASD Treatment with Regencell's Natural TCM Formulae

Millions of children globally are diagnosed with ADHD and/or Autism Spectrum Disorder (ASD), and many of them also suffer from additional mental, emotional, or behavioral conditions. While therapy and medication are commonly prescribed, these drugs can come with side effects such as sleep disturbances, appetite loss, headaches, stomach issues, and mood swings.

To address this unmet need for a natural and holistic treatment for neurocognitive disorders, Regencell is conducting efficacy trials on its standardized Traditional Chinese Medicine (TCM) formulae.

Regencell's TCM Formulae

Regencell's TCM formulae are all-natural liquid TCM treatments for ADHD and ASD. In its latest trial, the formulae were given to children twice daily for three months.

Developed by a TCM practitioner based on the Sik-Kee Au TCM Brain Theory®, the formulae contain only natural ingredients and have been used for over 30 years to treat a range of neurological illnesses and disorders, including ADHD and ASD, with positive results.

According to the TCM brain theory, disruptions in blood flow and damage to the central nervous, endocrine, and circulatory systems can impact the production of hormones and transmission of neurotransmitters like melatonin, dopamine, and norepinephrine. This results in poor encoding and decoding of functions, causing the social behaviors characteristic of ADHD and ASD.

Regencell Bioscience Holdings is an early-stage company focused on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders, including ADHD and ASD, and infectious diseases like COVID-19. The company has already completed a study on personalized TCM formulae for ADHD and ASD in Hong Kong and plans to launch three liquid-based TCM formulae for mild, moderate, and severe cases of ADHD and ASD, starting in Hong Kong and expanding to other markets as appropriate. Regencell has also formed a joint venture to offer COVID-19 treatments in various countries in Asia, India, Japan, Australia, and New Zealand. For more information, visit their websites at www.regencellbioscience.com and www.regencellasia.com.

Revolutionizing ADHD and ASD Treatment with Regencell's Natural TCM Formulae

Millions of children globally are diagnosed with ADHD and/or Autism Spectrum Disorder (ASD), and many of them also suffer from additional mental, emotional, or behavioral conditions. While therapy and medication are commonly prescribed, these drugs can come with side effects such as sleep disturbances, appetite loss, headaches, stomach issues, and mood swings.

To address this unmet need for a natural and holistic treatment for neurocognitive disorders, Regencell is conducting efficacy trials on its standardized Traditional Chinese Medicine (TCM) formulae.

Regencell's TCM Formulae

Regencell's TCM formulae are all-natural liquid TCM treatments for ADHD and ASD. In its latest trial, the formulae were given to children twice daily for three months.

Developed by a TCM practitioner based on the Sik-Kee Au TCM Brain Theory®, the formulae contain only natural ingredients and have been used for over 30 years to treat a range of neurological illnesses and disorders, including ADHD and ASD, with positive results.

According to the TCM brain theory, disruptions in blood flow and damage to the central nervous, endocrine, and circulatory systems can impact the production of hormones and transmission of neurotransmitters like melatonin, dopamine, and norepinephrine. This results in poor encoding and decoding of functions, causing the social behaviors characteristic of ADHD and ASD.

Regencell Bioscience Holdings is an early-stage company focused on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders, including ADHD and ASD, and infectious diseases like COVID-19. The company has already completed a study on personalized TCM formulae for ADHD and ASD in Hong Kong and plans to launch three liquid-based TCM formulae for mild, moderate, and severe cases of ADHD and ASD, starting in Hong Kong and expanding to other markets as appropriate. Regencell has also formed a joint venture to offer COVID-19 treatments in various countries in Asia, India, Japan, Australia, and New Zealand. For more information, visit their websites at www.regencellbioscience.com and www.regencellasia.com.

Revolutionizing ADHD and ASD Treatment with Regencell's Natural TCM Formulae

Millions of children globally are diagnosed with ADHD and/or Autism Spectrum Disorder (ASD), and many of them also suffer from additional mental, emotional, or behavioral conditions. While therapy and medication are commonly prescribed, these drugs can come with side effects such as sleep disturbances, appetite loss, headaches, stomach issues, and mood swings.

To address this unmet need for a natural and holistic treatment for neurocognitive disorders, Regencell is conducting efficacy trials on its standardized Traditional Chinese Medicine (TCM) formulae.

Regencell's TCM Formulae

Regencell's TCM formulae are all-natural liquid TCM treatments for ADHD and ASD. In its latest trial, the formulae were given to children twice daily for three months.

Developed by a TCM practitioner based on the Sik-Kee Au TCM Brain Theory®, the formulae contain only natural ingredients and have been used for over 30 years to treat a range of neurological illnesses and disorders, including ADHD and ASD, with positive results.

According to the TCM brain theory, disruptions in blood flow and damage to the central nervous, endocrine, and circulatory systems can impact the production of hormones and transmission of neurotransmitters like melatonin, dopamine, and norepinephrine. This results in poor encoding and decoding of functions, causing the social behaviors characteristic of ADHD and ASD.

Regencell Bioscience Holdings is an early-stage company focused on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders, including ADHD and ASD, and infectious diseases like COVID-19. The company has already completed a study on personalized TCM formulae for ADHD and ASD in Hong Kong and plans to launch three liquid-based TCM formulae for mild, moderate, and severe cases of ADHD and ASD, starting in Hong Kong and expanding to other markets as appropriate. Regencell has also formed a joint venture to offer COVID-19 treatments in various countries in Asia, India, Japan, Australia, and New Zealand. For more information, visit their websites at www.regencellbioscience.com and www.regencellasia.com.

$RGC :Thriving Biotech and Bioscience Industry
The financial markets have been on a roller coaster ride over the past few months, with investors navigating a volatile landscape of economic uncertainty, political tension, and global health crises. As the world continues to grapple with the ongoing COVID-19 pandemic, many industries have been hit hard by the resulting economic downturn.

Despite these challenges, some sectors have managed to weather the storm and even thrive in these trying times. One such industry that has seen significant growth in recent months is the biotechnology and bioscience sector.

According to a 2022 McKinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, nearly doubling the $16 billion raised in 2020. This trend is likely to continue as investors look for growth opportunities in an otherwise uncertain market.

One company that has stood out in this space is Regencell Bioscience (NASDAQ: RGC), a Hong Kong-based biotech firm focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

Since its listing on NASDAQ in mid-July 2021, Regencell has seen its share prices climb by approximately 247.31%, even as market conditions have slowed down over the past year. This impressive performance is a testament to the company's solid fundamentals and growth prospects.

Regencell's focus on TCM is particularly noteworthy, as the use of complementary and alternative medicine (CAM) has been on the rise in recent years. According to a study conducted by the U.S. Centers for Disease Control (CDC), nearly 40% of American adults used some form of CAM medication in 2004. With the advancements in technology and AI, this figure is likely to be even higher today.

Regencell's innovative approach to TCM is reflected in its impressive list of clinical trials and research programs. For example, the company's EARTH Trial has shown that RGC-COV19TM, an TCM formula, is an effective treatment for the alleviation and elimination of COVID-19 symptoms within 6 days. This not only helps to reduce the risk of hospitalization and death, but also demonstrates the potential of TCM in addressing unmet medical needs.

The company's leadership team, led by founder and CEO Yat-Gai Au, has also been instrumental in its success. With a shared vision and a team of experts dedicated to developing safe and effective treatments, Regencell is well-positioned to continue its growth trajectory in the years to come.

In fact, Au has been consistently buying shares of RGC in the open market, using his own money to alleviate short and distort investing schemes used on the company's stocks which in the long term can negatively hurt overall stock performance. This is a clear indication of the CEO's belief in the company's future and its potential.

Overall, Regencell Bioscience is an exciting growth-oriented company with a clear vision to help people improve their lives through TCM. As the world continues to face economic and health challenges, companies like Regencell that offer innovative solutions and a strong leadership team are well-positioned to succeed in the long-term. Investors looking for growth opportunities in the biotech sector should definitely keep an eye on RGC.

https://www.benzinga.com/general/entertainment/22/05/27291606/sector-rotation-and-9-stocks-to-watch-during-a-recession?SNAPI

$RGC: A Driving Force in the Thriving Biotech Industry

The biotechnology and bioscience industry has been on a roll in recent months, with many companies experiencing unexpected success despite the faltering stock market. Analysts attribute this success to a combination of factors, including advancements in data science, machine learning, and instrumentation, which are facilitating quicker and more reliable drug development breakthroughs.

According to a 2022 McKinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, doubling the $16 billion raised in 2020. This trend is expected to continue, with venture capital companies investing more than $52 billion in therapeutic-based biotech companies between 2019 and 2021.

One such company that has been making waves in the industry is Regencell Bioscience. As an early-stage bioscience company, Regencell is focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations. The company has become a leader in the field, and is striving to alleviate the unmet medical needs of millions of people around the world.

Regencell went public through an Initial Public Offering on the stock market in July 2021, and since then, its share prices have climbed by approximately 247.31%, despite market conditions slowing down since the start of the year. The company's chairman and CEO, Yat-Gai Au, has also been actively buying company shares from the open market to alleviate short and distort investing schemes, which can negatively affect overall stock performance in the long term.

The biotechnology and bioscience industry is proving to be a reliable investment, even in times of economic downturn. As the sector continues to advance and innovate, it is likely to play a significant role in driving the next bull market. With companies like Regencell leading the way, the future looks bright for the industry.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.

But so far, large companies are shying away from treating the condition.

Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.

Long Covid Treatments: Up To 23 Million
Axcella, Ampio, Regencell and Tonix include long Covid treatments in their pipelines. First Wave is working on gastrointestinal side effects of Covid-19. Aim is testing out a treatment for Covid-19 patients with cancer. Humanetics is looking at lung injuries in Covid-19 patients.

The U.S. Government Accountability Office estimates up to 23 million people in the U.S. have long Covid. Research is still in its infancy, though. Not every Covid-19 case is diagnosed. Further, symptoms of long Covid vary and manifest themselves differently in each person.

The phenomenon isn't new. Survivors of the original SARS virus have reported chronic fatigue four years after the initial infection. The GAO estimates the post-Covid condition could push 1 million Americans out of the workforce, highlighting the need for long Covid treatments.

https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/

Sector rebalancing and nine stocks to keep an eye on amid a downturn.

The commonly accepted definition of a recession is a brief period of decreased commerce and manufacturing activity that is typically indicated by a dip in GDP over two consecutive quarters. The GDP shrank at an annual pace of 1.4 percent, down from 6.9 percent in the fourth quarter of 2021, according to the Bureau of Economic Analysis.

Although the macro picture is at best gloomy, it is important to comprehend the larger market dynamics that show where money is moving, such as the economic cycle and sector rotation.

A recession is a well-known natural component of an expanding economy and a stage of the economic cycle. The economy's transition from a growth stage to a recession and back to growth is known as the economic cycle. Since it directly affects stock prices in relation to corporate profitability, this is perhaps the factor with the most impact on the overall markets.

The numerous market sectors, each of which is responsive to a distinct stage of the cycle, are what link the stock market to the economic cycle.

Are you still perplexed? This ought should make it simple.

When the economy is expanding, some industries (such as real estate, consumer brands, and consumer goods) will perform better than others (Healthcare, Food, Consumer Staples, Utilities)

This is referred to as sector rotation or the movement of capital by investors throughout the course of the economic cycle.

Investors typically shift into less cycle-sensitive sectors, such consumer staples and utilities, when the economy is headed for a recession. These sectors are referred to as defensive sectors because they can provide a certain level of protection during a recession.

Some of those defensive names include:

Coca-Cola Co
Albertsons Companies Inc
Altria Group Inc
NRG Energy Inc
PG&E Corporation
Clearway Energy Inc
National HealthCare Corporation
HealthStream, Inc
Regencell Bioscience Holdings Ltd
On the other hand, after a recession ends, investors switch to stocks with a high cycle sensitivity, including industrials and consumer cyclicals.

This is because these sectors tend to benefit from economic growth and increasing consumer spending. Companies in these sectors, such as technology, consumer discretionary, and financials, typically see their profits and stock prices rise as the economy recovers.

When selecting stocks to invest in during a recession, it is important to consider a company's financial health, including its cash flow, debt levels, and overall financial position. In addition, it is important to consider the company's business model and how it may be affected by a recession.

As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

Regencell Bioscience has a solid financial position, with a strong balance sheet and cash flow, making it well positioned to weather an economic downturn. The company also has a diverse business model, with a focus on both traditional and alternative medicine, which may be less affected by a recession than other industries.

https://www.benzinga.com/general/entertainment/22/05/27291606/sector-rotation-and-9-stocks-to-watch-during-a-recession?SNAPI

Regencell Bioscience is a Hong Kong-based company that is focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations. The company, led by its Chairman and CEO, Yat-Gai Au, has a clear vision to help people improve their lives through the use of TCM.

Regencell has become a leader in the field, spearheading the efforts to alleviate the unmet medical needs of millions of people around the world. Through their research and development programs, the company is working to develop treatments for ADHD and ASD patients, as well as for infectious diseases that affect the human immune systems.

Recently, the company has been gaining attention for its clinical trials, specifically the EARTH Trial, which has shown that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This not only helps to reduce the symptoms for patients, but also reduces the risk of hospitalizations and death. These results have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.

Yat-Gai Au believes that it is crucial to have the right team in place in order to remain true to the company's values and continue to head in the right direction. The Regencell team is dedicated to ensuring that their services and products are effective, safe, and useful for their patients.

In addition to their commitment to TCM research and development, Regencell is also focused on the commercialization of their products. The company recently went public through an Initial Public Offering on the stock market, and since then, the company's shares have grown by approximately 247.31%.

Despite turbulent market conditions, Regencell is comfortably poised for growth. Yat-Gai Au and the majority of shareholders are insider investors, and have recently invested more than $5.9 million in the company, showing their confidence in the future of Regencell Bioscience

https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

Regencell Bioscience's RGC-COV19TM: A Safe and Effective Solution for Reducing and Eliminating COVID-19 Symptoms.

Regencell began its investigational approach towards COVID-19 treatment when a friend of Regencell contracted COVID-19 in March 2020. To treat his friend, the TCM Practitioner used his proprietary TCM formula which he has been using over the past 30 years to treat various cold and flu patients, including during the 2003 SARS outbreak. The TCM Practitioner subsequently treated 9 voluntary COVID-19 patients in the United States using the proprietary TCM formula.

Study results showed that the treatment was effective. As Regencell has a mission to save lives, improve patients’ well-being and address unmet needs in the market, Regencell aims to make its natural and holistic treatment available to everyone in need.

From March 2020 to August 2021, Regencell set up protocols and procedures to conduct the EARTH efficacy trial in Malaysia and the United States.

RGC-COV19TM is designed to reduce COVID-19 symptoms such as fever, fatigue, cough, sore throat, runny nose, headache, nausea, chills, drowsiness, shortness of breath, persistent chest pain and muscle ache as the medicine works to (i) reduce and clear the mucus and phlegm from the upper respiratory system; (ii) dispel exterior viral pathogen via heavy sweats, urine and excrement; (iii) clear endogenous and liver heat; (iv) detox the liver; and (v) improve body circulation. By applying the TCM Practitioner’s “Sik-Kee Au TCM Brain Theory®”, RGC-COV19TM is also designed to remove blood clots from the brain and restore the patient's brain functions.

RGC-COV19TM (RGCA-CV01) is administered at 1 dose of RGCA-CV01-1Na (approximately 230ml) and 1 dose of RGCA-CV01-2Da (approximately 230ml) each time, with 1 dose of RGCA-CV01-1Na to be taken starting from the night of the first day of treatment and 1 dose of RGCA-CV01-2Da to be taken after lunch the next day, until symptoms are eliminated.

About RGC-COV19TM

RGC-COV19TM (RGCA-CV01) is an investigational, natural, orally administered liquid formula which aims to reduce and eliminate COVID-19 symptoms.

RGC-COV19TM is a natural formula designed by the TCM Practitioner according to the TCM Practitioner’s brain theory known as “Sik-Kee Au TCM Brain Theory®” and can be taken safely for two to three weeks. In conducting EARTH, the treatment was limited to 6 days in order to evaluate its efficacy in reducing and eliminating COVID-19 symptoms. The “TCM Practitioner” refers to our strategic TCM research partner, Sik-Kee Au, father of our founder and Chief Executive Officer.

According to the brain theory, brain functions depend on the oxygen level required for the brain to perform normal cognitive functions. For optimal brain performance, the heart needs to function normally to deliver sufficient oxygen to the brain. When the heart is weakened, the heart’s ability to deliver enough blood to circulate oxygen throughout the body is impaired. When this happens, brain functions are suppressed, resulting in a person experiencing fatigue, nausea, disorientation and reduced immune response.

RGC-COV19TM is designed to strengthen the heart’s functions. According to the brain theory, when the heart is strengthened, it increases blood flow and delivers more oxygen to the brain, resulting in reduced blood clots and restored brain functions. Regardless of the COVID-19 variant, the lungs and heart are where the coronavirus does much of its damage by setting off an inflammatory immune response that ravages infected and uninfected cells alike, leading to tissue scarring and oxygen deprivation which in turn suppress brain functions. RGC-COV19TM is formulated to generate more responsive cognitive functions which in turn stimulate the body’s own healing mechanism.

"Riding the Waves of Uncertainty: Finding Prosperous Stocks for Any Economy"

When the economy is uncertain, many investors search for recession-resistant stocks. These are companies that have a track record of performing well during economic downturns. While "recession-proof stocks" may not exist, investors can look for companies that have proven to be resilient during tough economic times.

Typically, recession-resistant stocks come from defensive sectors such as Consumer Staples, Utilities, and Health Care. These sectors are less affected by changes in interest rates and economic growth and often provide essential products and services that consumers continue to purchase during a recession. For example, people still need to buy groceries and pay for utility bills regardless of the state of the economy.
Currently, the Energy sector is performing well due to rising oil prices, supply chain concerns, and increased demand for gas, energy equipment, and services. However, it's worth noting that past performance is not a guarantee of future results.

When researching potential investments, it is important to look beyond surface-level returns and examine individual companies within a sector to identify those that may be well-positioned to weather an economic downturn. Some key factors to consider include a company's financial stability, diversified revenue streams, and strong management team.
For instance, in the Consumer Staples sector, companies like Coca-Cola, PepsiCo, Constellation Brands, Albertsons Companies, SpartanNash, Andersons and British American Tobacco that have a diversified product portfolio and a strong brand reputation may be better positioned to weather an economic downturn than those that rely heavily on a single product or brand. In the utilities sector, companies like NRG Energy, DTE Energy, OGE Energy, PG&E Corporation, Black Hills Corp, Exelon Corporation, Clearway Energy, NextEra Energy and First Solar, Inc that have a diverse mix of generation sources and regulated assets may be better insulated from market fluctuations than those that rely heavily on a single source of revenue.

In the Healthcare sector, companies like National HealthCare Corporation, Davita Inc, Alignment Healthcare Inc, Sophia Genetics, Computer Programs & Systems, HealthStream, Viatris, Regencell Bioscience Holdings and Prestige Consumer Healthcare that have a strong pipeline of products in development and a track record of innovation may be better positioned to weather an economic downturn than those that rely heavily on a single drug or therapy.

It's worth noting that even though these stocks are considered "recession-resistant" it doesn't mean they can't go down, but they tend to be less affected than other sectors. It's also important to diversify your portfolio and not to put all your eggs in one basket. Always consult with a financial advisor and conduct your own research before making any investment decisions.

Original link:

https://www.benzinga.com/news/small-cap/22/05/27083377/27-recession-resistant-stocks-to-hold-through-tough-times

"The Ins and Outs of CEO Stock Purchases: A Look at Regencell Bioscience"

A CEO may buy shares in their own company for a variety of reasons, including seeing the stock as undervalued and wanting to demonstrate confidence in the company's prospects to the market. When a CEO buys shares in their own company, it sends a signal to the market that they believe the stock is undervalued and that the company has a bright future ahead. This can help to boost investor confidence and drive up the stock price.

Another reason for a CEO to buy shares in their own company is to align their interests with those of shareholders. Some companies may require their senior executives to purchase a certain number of shares in the company in order to ensure that they are acting in the best interests of the shareholders. By holding a significant number of shares in the company, a CEO is more likely to make decisions that will benefit the company and its shareholders in the long-term.

In the case of Regencell Bioscience, the company's Chairman and CEO, Mr. Yat-Gai Au, has taken a particularly transparent and shareholder-aligned approach. Since the company's incorporation in October 2014 up to the IPO, the company has been fully funded by Mr. Au. Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50. He pledged not to draw salary and bonus of more than USD $1 until the company reaches USD $1 billion market capitalization. He also will not award share options for himself.

Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,010 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million). This shows his commitment to the company, and it clearly demonstrates that his interests are aligned with those of the shareholders. By investing his own money in the company, he is also signaling to the market that he believes in the company's future and that the stock is undervalued. This can help to boost investor confidence and drive up the stock price. Overall, the CEO buying shares in their own company is a positive signal for investors and can be a sign of a company with a bright future ahead.

https://www.forbes.com/advisor/investing/stock-buyback/#:~:text=A%20stock%20buyback%20is%20when,fund%20operations%20and%20other%20investments

https://www.quora.com/Why-would-a-CEO-buy-shares-in-their-company-when-the-company-stock-is-selling-off/answer/William-Elliott-29?ch=10&oid=336350002&share=85576911&srid=hIzcnI&target_type=answer

https://newsfilter.io/articles/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo-3b36a9b6af854a3aa5240d3148ccbd

"Exploring the Benefits of AI and VR in Healthcare and Alternative Medicine: Insights from RGC CEO"

As the world of technology continues to evolve at a rapid pace, healthcare providers and alternative medicine practitioners are looking for ways to safely adopt new innovations to improve patient outcomes. Artificial Intelligence (AI) and Virtual Reality (VR) are at the forefront of this movement, and businesses that fail to maximize their capabilities risk falling behind in the highly competitive marketplace.

The rise of the Internet-of-Things (IoT), mobile communication, and 5G tools have greatly contributed to the expansion of these technologies across multiple fields. While initially, it was believed that these developments would mainly be used in advanced industries such as military, security, engineering, architecture, and aviation, the need for state-of-the-art tools has quickly manifested itself within the healthcare and alternative medicine market.

AI and Traditional Chinese Medicine (TCM) are a perfect example of how these technologies can be used together in a complementary way. By incorporating AI into TCM, practitioners can make more accurate diagnoses and develop more effective treatment plans. Additionally, AI can be used to monitor patients' progress and adjust treatment plans as needed.

In the sphere of virtual reality, it's now possible for clinical and medical personnel to combine different technologies to enhance their multisensory working environment. The adoption of virtual or augmented reality tools has also been found to help alleviate stress, anxiety, and burnout experienced by healthcare workers. Telemedicine has become increasingly popular during the pandemic, as it allows for online medical consultations, enabling doctors to continue seeing and treating patients from the comfort of their own homes.

While the ongoing development and opportunities seem endless, it is essential to ensure that these technologies are safely adopted in the healthcare and alternative medicine fields. The benefits are clear, but the security and privacy of patients must be a top priority. As we continue to explore these exciting new frontiers, it is vital to work together and learn from one another to achieve the best possible outcomes for patients.

https://www.entrepreneur.com/en-in/technology/how-can-healthcare-and-alternative-medicine-safely-adopt/439152

$RGC - Growth-oriented company with a clear vision to help people improve their lives.

As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

"For our company to remain true to what we believe in, and continue to head in the right direction, it's critical to have the right set of people with a shared value of interests. Our team develops programs and leads scientific trials to ensure our services and products are effective, safe and useful," shares Yat-Gai.

The company has grown to be more than just a research and development facility for the treatment of neurocognitive disorders and degenerations. "It's paving the way for extraordinary improvements in TCM to be mainstream. Why should only a small group of people or communities have access to these groundbreaking treatments?"

In a recent clinical study - EARTH Trial - results showed that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This in return helps to reduce the risks of hospitalizations and death. The rigorous trials have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.

https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

The Downturn For Big Pharma

The bullish turn for biotech since June has come in lockstep with a downturn for Big Pharma stocks. Just three months ago, the pharmaceuticals group ranked No. 34 out of 197. It has now tumbled 100 spots, ranking No. 134.
Earlier this year, rising interest rates and inflation worries sent investors
scrambling for less risky stocks. In the world of medicine, Big Pharma fits that bill. Pharmaceutical companies sell widely used products like cholesterol and cancer drugs.

Biotech companies, on the other hand, are working on cutting-edge treatments where losses outnumber game-winning touchdowns. Then, investors “cared a lot more about businesses that have predictable cash flows today, as opposed to the businesses that have the promise of really big predictable cash flows in the future,” Swalla said.
“I think biotech and technology stocks suffered the same fate from an institutional-investor standpoint.” But now, experts say the paradigm
is shifting from a “risk off” environment favoring companies with stable, predictable cash flows to more growth-oriented plays.

And when it comes to growth, biotech tends to be among the most eye-catching segments.
Lee Brown, sector lead for health care at research firm Third Bridge,
says biotech stocks could actually offer investors a safe haven amid
economic uncertainty. “If you’re worried about the economic climate for next year, then being in more idiosyncratic growth sectors is right out of the portfolio manager playbook,” he told IBD. Eric Schiffer, who chairs private
equity firm The Patriarch Organization, has a more measured view. He says biotech remains tied to macroeconomic woes, but these stocks have been more beat-up than others and could offer investors a low point for entry. “What we do know is there’s incredible discoveries ahead that will be worth millions of dollars,” he said. “We’re in a cycle. This is a cycle that will see a bull period ahead. We just don’t know when. If investors have a long enough ride, they can do fine. They’re getting in at great valuations.”
https://www.investors.com/

Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19. Regencell has completed its first research study using personalized TCM formulae for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently in other markets as it deems appropriate. The Company has formed a joint venture to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. For more information, please visit www.regencellbioscience.com and www.regencellasia.com.

Despite the stock market downturn, the biotech industry has shown resilience and is expected to continue growing, according to experts.

Numerous biotech firms, from top-rated Catalyst Pharmaceuticals to powerhouses like Neurocrine Biosciences and BioMarin Pharmaceutical, down to relatively unheard-of Karuna Therapeutics, are soaring like it's a fresh bull market despite the faltering stock market. The unexpected success of the biotech companies is the result of numerous factors, not just one spark. Analysts believe that is encouraging for their long-term viability.

Regardless of how stock prices fluctuate on any given day, Loncar told Investor's Business Daily that the underlying news that determines whether biotech is moving forward or backward has recently been all positive. "Everything is pointing in the right direction," He points out that, beginning in early last year, biotech equities were the first sector to experience a decline. They are now among the first people to turn around. The biotech sector group was placed 143rd out of 197 industries just six months ago, placing it in the lowest 25% of all industry groups. Since then, the sector's top biotech stocks have propelled it to a sixth-place ranking and a combined value of $1.2 trillion.

Can biotech drive the following bull market, then? According to Thomas Swalla, CEO of privately held Dotmatics, "It should." Dotmatics creates software to support businesses in the life sciences. Swalla points out that data science, machine learning, and instrumentation are all facilitating quicker and more reliable drug development breakthroughs. IBD quoted him as saying, "I absolutely don't see any reason why biotech can't be a significant influence in the future.

Many investors, who are willing to risk some of their portfolio shares to help stabilize their position in the event of a recession, have placed major bets on the biotechnology and bioscience industry in recent months. According to a 2022 Mckinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, doubling the $16 billion raised in 2020.

The same report found that between 2019 and 2021, even as the pandemic took hold of the global economy throughout the greater part of 2020, venture capital companies still invested more than $52 billion in therapeutic-based biotech companies.

Since Regencell was listed on NASDAQ in mid-July 2021, Regencell Bioscience founder and CEO, Yat-Gai Au has made purchases of ordinary company shares from the open market to alleviate the short and distort investing schemes used on the company's stocks which in the long term can negatively hurt overall stock performance. With millions of his personal finances already spent to purchase company shares, Yat-Gai Au shared why he's fully committed to this strategy and the future of the company.

About Regencell Bioscience
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.

On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.

Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.

https://www.investors.com/
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

A significant chance for exponential returns could be found in biotech stocks.

Biotech stocks are always in the spotlight as the sector itself has been the source of significant disruptions for the global healthcare system. Long sought after by both high-risk investors and low-risk investors, biotechnology stocks offer something that other stocks do not: highly speculative opportunities. Because many of these companies are involved in early phase trials of things like novel drugs, a positive result at any phase can end up producing a favorable reaction in the stocks market. And for biotech stock investors, this could be a big opportunity for exponential gains.

Regencell Bioscience, an early-clinical bioscience company which focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases which affects the immune system such as COVID-19.

The company have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. $rgc aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. They are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!

Nasdaq Listing

On July 16, 2021, the ordinary shares began trading on the Nasdaq Capital Market. The company raised net proceeds of approximately $19.3 million from the initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per share. They plan to use these proceeds to fund for the second research study (currently ongoing), TCM formulae and products, staff salaries, product and intellectual property registrations, facilities rental, renovations and equipment, for working capital and other general corporate purposes.
https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html

Why Is This Biotech Stock Worth a Look?

RGC launched a follow-up research for their experimental liquid formula RGC-COV19TM in the treatment of COVID-19 symptoms on May 18, 2022. (EARTH-B Trial). The second study expanded on the encouraging findings from the initial EARTH experiment (EARTH-A Trial), which was carried out in 2020–2021. In the two studies, 95.5 percent of the participants (n=81) reported complete symptom relief six days after therapy, with the exception of occasional coughing and loss or reduction in sensation of taste and/or smell (sensory dysfunction).

RGC anticipates publishing data from its second clinical research of its standardised TCM formula for the treatment of ASD and ADHD in the coming months.

In order to set standards for therapy, dosing, adverse effects (AEs), and assessing patient response in a methodical and reproducible manner, Regencell Bioscience's initial clinical study was created. Seven adolescents with clinically confirmed ASD or ADHD, ranging in age from five to eleven, participated in the 2018–2019 study. Subjects got a personalized TCM formula for up to three months after stopping all current treatments and medications. Parental interviews and four validated assessment tools, such as the Autism Treatment Evaluation Checklist (ATEC), Gilliam Autism Rating Scale (GARS), Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS), and Pelham (SNAP)-IV 26-item Parent Rating Scale, were used to gauge the responses of the patients (SNAP-IV-26). During the course of treatment, all seven patients showed a reduction in symptoms on all four scales.

The second clinical trial assesses how three standardized TCM formula mixes (for mild, moderate, and severe impairment) respond to children in the same age group. Weekly practitioner meetings, twice daily medication for three to twelve months, and monthly assessments are all part of the study's design. The outcomes will be used to submit a proprietary Chinese medicine (pCm) registration application in Hong Kong, making the product available for purchase both over the counter and in other clinic.

To support its findings, Regencell is concentrating on its clinical research. Through these initiatives, the infrastructure for manufacturing and the supply chain that is needed to obtain pCm registration will be built. The commercialization of Regencell Bioscience's standardised formulations and pCm registration in Hong Kong are both subject to a four-year timeline. A lot of tasks lie ahead for the company:

•Finishing its second clinical trial and reviewing outcomes.
• Running more clinical studies to support the use of its patented formulas for ASD/ADHD and other uses.
• Getting IP protection in Hong Kong and other markets through the acquisition of patents and other types of IP.
• Setting up a manufacturing infrastructure and supply chain that complies with registration criteria.
• Compiling and filing paperwork for pCm approval.
• Develop the infrastructure and marketing and distribution plan.
We are encouraged by RGC's thoughtful, methodical approach to developing its therapies and communicating its progress to shareholders, which we believe may be a sign of greater things to come as it moves towards commercialization. RGC's steady share price ascent in recent weeks.
• Completing its second clinical trial and evaluating results.
• Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.
• Obtaining patents and other forms of IP protection in Hong Kong and other markets.
• Establishing manufacturing capability and supply chain that will meet registration requirements.
• Assembling and filing documentation for pCm approval.
• Build out its marketing and distribution strategy and infrastructure.
•
RGC’s steady share price ascension in recent weeks may be a sign of greater things to come as its moves towards commercialization, we are encouraged by its thoughtful, systematic approach to developing its therapies, and communicating its progress to shareholders.

https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html

$RGC CEO spent millions of his personal finances on purchasing company shares.

Since the company went public, Yat-Gai, the CEO of Regencell Bioscience $RGC, has noticed that short and distort organizations or individuals are starting to affect their stock price and sentiment.

"Companies like ours are not given the opportunity to prove themselves since the culprits are driving down the value of smaller companies, causing the market and general public to lose its confidence. This causes damage to our company, particularly the patients, some who are desperate for a solution," he said.

To help mitigate the negative effects of such short-term schemes, Yat-Gai managed to purchase more than $5.9 million worth of ordinary company shares. To date, Yat-Gai Au is the majority shareholder, with an 81% stake in the company. This leaves around 19% of shares owned by other shareholders.

"To date, I have spent millions of my personal finances on purchasing RGC shares. My most recent purchase was worth $886,000 of RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the company and its future and intend to continue to put my money where my mouth is and increase my shareholdings."

Seeing as majority ownership is held within the company, oftentimes referred to as 'Insider Ownership,' it allows them to have better control over critical decision-making issues that can help fast-track the company's overall development goals.

"The decision to repeatedly purchase RGC shares over the last several months is to support and ensure the potential of the company can be met for years to come. We've vested a lot of time, energy, and resources in Regencell, and we're well aware of the potential difference it can make in the field of alternative medicine. I believe that as I lead the way our company will be able to meet the goals we've set out to achieve within the coming years."

The long-term transactions not only give the company better control over critical decision-making but enables them to boost investor sentiment.

https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

"Biotech Sector Proves Resilient Amid Faltering Stock Market, Experts Predict Continued Growth"
Numerous biotech firms, from top-rated Catalyst Pharmaceuticals to powerhouses like Neurocrine Biosciences and BioMarin Pharmaceutical, down to relatively unheard-of Karuna Therapeutics, are soaring like it's a fresh bull market despite the faltering stock market. The unexpected success of the biotech companies is the result of numerous factors, not just one spark. Analysts believe that is encouraging for their long-term viability.

Regardless of how stock prices fluctuate on any given day, Loncar told Investor's Business Daily that the underlying news that determines whether biotech is moving forward or backward has recently been all positive. "Everything is pointing in the right direction," He points out that, beginning in early last year, biotech equities were the first sector to experience a decline. They are now among the first people to turn around. The biotech sector group was placed 143rd out of 197 industries just six months ago, placing it in the lowest 25% of all industry groups. Since then, the sector's top biotech stocks have propelled it to a sixth-place ranking and a combined value of $1.2 trillion.

Can biotech drive the following bull market, then? According to Thomas Swalla, CEO of privately held Dotmatics, "It should." Dotmatics creates software to support businesses in the life sciences. Swalla points out that data science, machine learning, and instrumentation are all facilitating quicker and more reliable drug development breakthroughs. IBD quoted him as saying, "I absolutely don't see any reason why biotech can't be a significant influence in the future.

Many investors, who are willing to risk some of their portfolio shares to help stabilize their position in the event of a recession, have placed major bets on the biotechnology and bioscience industry in recent months. According to a 2022 Mckinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, doubling the $16 billion raised in 2020.

The same report found that between 2019 and 2021, even as the pandemic took hold of the global economy throughout the greater part of 2020, venture capital companies still invested more than $52 billion in therapeutic-based biotech companies.

Since Regencell was listed on NASDAQ in mid-July 2021, Regencell Bioscience founder and CEO, Yat-Gai Au has made purchases of ordinary company shares from the open market to alleviate the short and distort investing schemes used on the company's stocks which in the long term can negatively hurt overall stock performance. With millions of his personal finances already spent to purchase company shares, Yat-Gai Au shared why he's fully committed to this strategy and the future of the company.
About Regencell Bioscience
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.

On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.

Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.

https://www.investors.com/
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

Things to Consider When Analyzing Small-Cap Stocks
Management Quality: A competent management team is essential for any company, let alone a smaller one trying to establish itself in the market. Potential investors should undertake some basic online research on the key people within the company, such as the CEO and chief financial officer (CFO). Do they have a track record of running successful businesses? Also, see if the leadership team owns shares in the company. Company insiders owning stock indicates a commitment to success and aligns their interests with those of the shareholders.

Growing Sales: Small-cap companies typically have limited cash flow—therefore, they must generate healthy sales. As a rule of thumb, small-cap investors should look for stocks with an annual revenue growth rate of at least 20%, which indicates that a company has the potential for disruptive innovation within its industry and is well positioned to generate a future profit. Investors can find this information on Yahoo! Finance under the "Financials" tab, which shows a company's revenue for the past three years.

High Operating Margins: A company's operating margin represents how efficiently it can generate profit through its primary operations before paying interest and tax. When investing in small caps, it is a good idea to look for consistently increasing operating margins, as this indicates that a company is good at turning sales into profits.

Advantages of Small-Cap Stocks
Growth Potential: Small-cap stocks provide investors with significant upside by getting in early before a company potentially goes on to become an industry leader. Moreover, small-cap stocks with a market capitalization of under $1 billion can double in value much easier than companies like Amazon or Apple that have $1 trillion-plus market caps, as it takes far less money to move their share price. Additionally, a small-cap stock that goes on to realize rapid growth can gain the attention of Wall Street analysts and institutional investors, which can increase shareholder returns even further.

Less Competition from Larger Investors: Institutional investors, such as banks, hedge funds, and REITs, typically stick to investing in large-cap stocks, often overlooking many small-cap opportunities. This allows retail investors to buy the story of a future company of tomorrow without competing with traditional Wall Street money.

One ticker that has a small market cap ($412.35M) and a CEO who is holding 81% of the stock is Regencell Bioscience ($RGC).
To get a sense of who is truly in control of Regencell Bioscience Holdings Limited (NASDAQ:RGC), it is important to understand the ownership structure of the business. With 81% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises.

Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.

Let's take a closer look to see what the different types of shareholders can tell us about Regencell Bioscience Holdings.

What Does The Lack Of Institutional Ownership Tell Us About Regencell Bioscience Holdings?
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.

There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company.
https://www.investopedia.com/investing/top-small-cap-stocks/

This stock has an ongoing growth potential despite pandemic and recession.

As countries across the world have in recent months lifted all, or remaining pandemic-related restrictions and lockdowns, and as the COVID crisis looks to cool down, many health experts are not completely convinced that the pandemic has yet subsided.

At the start of July, the chief of the World Health Organization, Tedros Adhanom Ghebreyesus noted that a number of countries were still reporting a continuing rise in daily active cases, which in the long run can put severe pressure on public health systems and frontline workers.

While it's not yet clear when we will mark the end of the pandemic, Regencell Bioscience has made encouraging advances throughout the pandemic to establish new formulas and treatments for infectious diseases.

Separately, the company has been working on philanthropic projects that could help thousands of children who are in severe financial distress or have been impacted by COVID.

According to Yat-Gai, "In April, I started looking to provide grants and financial support to more than 10,000 children that have been financially impacted by COVID, and others affected with ADHD and ASD. Until now, I have managed to help over 150 children. This is a project I'm personally handling through the Regencell Foundation."

Investment in the future, whether through monetary means or philanthropic efforts, is slowly helping to reshape the human understanding of bioscience and biotechnology, and the impact it has to make a difference in the broader society it serves.

https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

As investors are on the lookout for cheap biotech stocks which may have great potential upside, the slow and steady performance of some companies may present viable financial returns in the coming years.

One company of interest in this specific category is Regencell Bioscience Holdings Limited (NASDAQ:RGC), an early-stage bioscience company focusing on the research, development, and commercialization of Traditional Chinese Medicine ("TCM").

Regencell Bioscience focuses on the research and development of neurocognitive disorders and degeneration, more specifically in ADHD, ASD, and infectious diseases such as COVID-19.

The bioscience company went public with around 2.6 million ordinary shares at $9.50 per share, raising approximately $22.7 million.

RGC has kept investors interested and has received media attention for all the right reasons; the most recent - the company's chairman and CEO, Yat-Gai Au used over $5.9 million of his personal funds to purchase ordinary RGC shares through the open market to support the growth and potential of the company.

Sizable stock purchases by insider investors, with the CEO being an exception, have helped the company sidestep short sellers and hedge fund managers that have been taking advantage of small-time investors. Currently, the company has just over 2.6 million shares on the market available for trade.

All directors and employees who were previously granted stock options have agreed to a further lock-up undertaking for an additional six months, until July 20, 2023, the second anniversary of the company’s initial public offering. Their shares will remain locked up until such date.

Regencell Bioscience's Path to Registration and Commercialization

Regencell Bioscience has a four-year timeframe to commercialize its standardized formulations and gain proprietary Chinese medicine (pCm) registration in Hong Kong. The Company has a number of tasks ahead:

• Completing its second clinical trial for ASD/ADHD and COVID, and evaluating results.

• Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.

• Obtaining patents and other forms of IP protection in Hong Kong and other markets.

• Establishing manufacturing capability and supply chain that will meet registration requirements.

• Assembling and filing documentation for pCm approval.

• Build out its marketing and distribution strategy and infrastructure.

We believe that an emphasis on conducting well-designed clinical trials that measure outcomes based on well-established assessment instruments, will provide Regencell Bioscience with a competitive advantage in terms of expertise and credibility in an industry that is moving towards higher standards for efficacy, safety and quality. While there is still much work to do, in our view, Regencell Bioscience is taking a thoughtful, systematic approach to developing its TCM formulae.

https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html

Biotech stocks could be a big opportunity for exponential gains.

Biotech stocks are always in the spotlight as the sector itself has been the source of significant disruptions for the global healthcare system. Long sought after by both high-risk investors and low-risk investors, biotechnology stocks offer something that other stocks do not: highly speculative opportunities. Because many of these companies are involved in early-phase trials of things like novel drugs, a positive result at any phase can end up producing a favorable reaction in the stock market. And for biotech stock investors, this could be a big opportunity for exponential gains.

Regencell Bioscience is an early-clinical bioscience company that focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases that affect the immune system, such as COVID-19.

The company has been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families, and caregivers and to become a market leader for the treatment of these disorders. rGC aims to achieve improvements in both symptoms and overall health of patients as compared to currently available medications on the market. They are passionate about transforming the lives of patients, their families and caregivers and helping them feel their best physically, mentally, and emotionally.

Nasdaq Listing
On July 16, 2021, the ordinary shares began trading on the Nasdaq Capital Market. The company raised net proceeds of approximately $19.3 million from the initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per share. They plan to use these proceeds to fund the second research study (currently ongoing), TCM formula and products, staff salaries, product and intellectual property registrations, facilities rental, renovations, and equipment, for working capital and other general corporate purposes.

The company launches three liquid based standardized TCM formula candidates for mild, moderate and severe ADHD and ASD patients. The company made a stellar performance after its IPO and gained 223% since then.

All directors and employees who were previously granted stock options have agreed to a further lock-up undertaking for an additional six months, until July 20, 2023, the second anniversary of the company's initial public offering. Their shares will remain locked up until such date.

Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.

But so far, large companies are shying away from treating the condition.

Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.

Long Covid Treatments: Up To 23 Million
Axcella, Ampio, Regencell and Tonix include long Covid treatments in their pipelines. First Wave is working on gastrointestinal side effects of Covid-19. Aim is testing out a treatment for Covid-19 patients with cancer. Humanetics is looking at lung injuries in Covid-19 patients.

The U.S. Government Accountability Office estimates up to 23 million people in the U.S. have long Covid. Research is still in its infancy, though. Not every Covid-19 case is diagnosed. Further, symptoms of long Covid vary and manifest themselves differently in each person.

The phenomenon isn't new. Survivors of the original SARS virus have reported chronic fatigue four years after the initial infection. The GAO estimates the post-Covid condition could push 1 million Americans out of the workforce, highlighting the need for long Covid treatments.

https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/

3 Reasons Why Companies or CEO Buy Back Stocks

1) Stock Buybacks Preserve the Stock Price
Shareholders usually want a steady stream of increasing dividends from the company. And one of the goals of company executives is to maximize shareholder wealth. However, company executives must balance appeasing shareholders with staying nimble if the economy dips into a recession.

Why do some favor buybacks over dividends? If the economy slows or falls into recession, a company might be forced to cut its dividends to preserve cash. The result would undoubtedly lead to a sell-off in the stock. However, if the bank decided to buy back fewer shares, achieving the same preservation of capital as a dividend cut, the stock price would likely take less of a hit.

Committing to dividend payouts with steady increases will undoubtedly drive a company's stock higher, but the dividend strategy can be a double-edged sword. In the event of a recession, share buybacks can be decreased more easily than dividends, with a far less negative impact on the stock price.

2) The Stock Is Undervalued
Another major motive for businesses to do buybacks is that they genuinely feel as if their shares are undervalued. Undervaluation occurs for several reasons, often due to investors' inability to see past a business' short-term performance, sensationalist news items, or a general bearish sentiment. For example, a wave of stock buybacks swept the United States in 2010 and 2011 when the economy was recovering from the Great Recession.

3) Many companies began making optimistic forecasts for the coming years, but company stock prices still reflected the economic doldrums that plagued them in years prior. These companies invested in themselves by repurchasing shares, hoping to capitalize when share prices finally began to reflect new, improved economic realities.

Stock Buybacks Consolidate Ownership
Companies issue shares to raise funding for projects. Several types of shares can be issued, but the two most popular are common and preferred shares. Common—also called ordinary—shares come with voting privileges and ownership. Preferred shares differ in that dividends are paid out to the shareholders before common shareholders, and these shareholders are higher in the queue for payout during a bankruptcy proceeding.

A company with thousands of stocks issued essentially has thousands of voting owners. A buyback reduces the number of owners, voters, and claims to capital.

If a stock is dramatically undervalued, the issuing company can repurchase some of its shares at this reduced price and then re-issue them once the market has corrected, thereby increasing its equity capital without issuing any additional shares. However, investors may be reluctant to purchase the re-issued shares if they feel they've been burned by a company this way.

RGC Ownership Breakdown

To get a sense of who is truly in control of Regencell Bioscience Holdings Limited (NASDAQ:RGC), it is important to understand the ownership structure of the business. With 81% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises.

Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.

Let's take a closer look to see what the different types of shareholders can tell us about Regencell Bioscience Holdings.

What Does The Lack Of Institutional Ownership Tell Us About Regencell Bioscience Holdings?
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.

There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company.

Hedge funds don't have many shares in Regencell Bioscience Holdings. With a 81% stake, CEO Yat-Gai Au is the largest shareholder. With such a huge stake, we infer that they have significant control of the future of the company. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, we're glad to see a company insider with such skin in the game. In comparison, the second and third largest shareholders hold about 7.6% and 0.1% of the stock.

Insider Ownership Of Regencell Bioscience Holdings
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company.

Most recent data indicates that insiders own the majority of Regencell Bioscience Holdings Limited. This means they can collectively make decisions for the company. So they have a US$430m stake in this US$531m business. Most would be pleased to see the board is investing alongside them.

General Public Ownership
With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Regencell Bioscience Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership
With a stake of 7.6%, private equity firms could influence the Regencell Bioscience Holdings board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

https://www.investopedia.com/ask/answers/042015/why-would-company-buyback-its-own-shares.asp

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-limited-nasdaqrgc-insiders-hav?utm_medium=article&utm_source=robinhood

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings#information

When the economy moves toward a recession, investors usually rotate into sectors that are less sensitive to the economic cycle.

Sector Rotation And 9 Stocks To Watch During A Recession
Coca-Cola Co $KO
Albertsons Companies Inc $ACI
Altria Group Inc $MO
NRG Energy Inc $NRG
PG&E Corporation $PCG
Clearway Energy Inc $CWEN
National HealthCare Corporation $NHC
HealthStream, Inc. $HSTM
Regencell Bioscience Holdings Ltd $RGC

The commonly accepted definition of a recession is a brief period of decreased commerce and manufacturing activity that is typically indicated by a dip in GDP over two consecutive quarters. The GDP shrank at an annual pace of 1.4 percent, down from 6.9 percent in the fourth quarter of 2021, according to the Bureau of Economic Analysis.

Although the macro picture is at best gloomy, it is important to comprehend the larger market dynamics that show where money is moving, such as the economic cycle and sector rotation.

A recession is a well-known natural component of an expanding economy and a stage of the economic cycle. The economy's transition from a growth stage to a recession and back to growth is known as the economic cycle. Since it directly affects stock prices in relation to corporate profitability, this is perhaps the factor with the most impact on the overall markets.

The numerous market sectors, each of which is responsive to a distinct stage of the cycle, are what link the stock market to the economic cycle.

Are you still perplexed? This ought should make it simple.

When the economy is expanding, some industries (such as real estate, consumer brands, and consumer goods) will perform better than others (Healthcare, Food, Consumer Staples, Utilities)

This is referred to as sector rotation or the movement of capital by investors throughout the course of the economic cycle.

Investors typically shift into less cycle-sensitive sectors, such consumer staples and utilities, when the economy is headed for a recession. These sectors are referred to as defensive sectors because they can provide a certain level of protection during a recession.

https://www.benzinga.com/general/entertainment/22/05/27291606/sector-rotation-and-9-stocks-to-watch-during-a-recession?SNAPI

Sometimes, investors buy stocks with heavy short interest to exploit the potential for a short squeeze, but the attempt to swing for the fences sometimes ends in disaster.

A short squeeze is an unusual condition that triggers rapidly rising prices in a security due to short sellers being forced to cover their positions by buying shares. For a short squeeze to occur, the security must have an unusual degree of short-sellers holding positions in it.

Generally, a rapid rise in the stock price could be attractive, but it is not without risks. Here’s how it works: Active traders monitor highly shorted stocks and watch for them to start rising. If the price picks up momentum, the trader jumps in to buy, trying to catch what could be a short squeeze and a significant move higher.

Short squeezes are arguably always a gamble. Over the years, some stocks have moved higher after they had a heavy short interest, while in other instances, they tumbled miserably.

RGC Short Interest Compared To GameStop?
The short squeeze of American video game retailer GameStop Corp.
GME in January 2021 took the market by storm, causing major financial consequences for some hedge funds and large losses for short-sellers.

Roughly 140% of the game retailer’s public float had been sold short. There was a mad rush to buy shares to cover those positions, which caused the price to rise further.

Although a number of hedge funds participated, the short squeeze was largely triggered by users of the subreddit r/wallstreetbets.

At the height of that episode, on January 28, 2021, the short squeeze caused the retailer’s stock price to reach a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of that month.

One ticker that some traders have looked at to also have short squeeze potential is Regencell Bioscience Ltd.
RGC

The short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year. In fact, Regencell has sometimes been more heavily shorted than GameStop, with occasional days close to 90% shorted.

Although Regencell and GameStop stocks’ short volume profiles might be considered to be similar, not as much is known about Regencell. As of May 16, the company’s founder and CEO held 10,539,159 ordinary shares, representing 81% of the total number of issued and outstanding ordinary shares in Regencell.

Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price. Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52. Where are all the extra shares coming from?

As witnessed on Reddit and other social media and forums, especially during the GameStop short squeeze, retail shareholders came together, driven by the community’s effort to punish market participants who make a living shorting and distorting public companies, causing them to stumble and fall.

CEO’s Conviction In RGC
Regencell Founder and CEO Yat-Gai Au’s believes in a better and brighter future for the company. He says he has demonstrated his commitment and confidence and his position against possible short and distort sellers by using his own money, amounting to over $5 million, to purchase Regencell shares. Moreover, he has support from Samuel Chen, a very successful early Zoom Video Communications, Inc. investor. Samuel owned 8.8% of Zoom shares and was the second largest individual investor.

To date, Mr. Au has converted his shareholders’ loan of $3.25 million to Regencell’s ordinary shares upon listing. He has also pledged not to draw a salary and bonus of more than $1 until Regencell reaches a $1 billion market capitalization and reserved share options for all employees except himself.

Additionally, to demonstrate commitment to Regencell, all directors and employees who were previously granted stock options upon Regencell’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.

Whether or not the ticker will encounter a short squeeze is anyone’s guess, but some traders are keeping their eyes on a host of companies that seem to have outsized short interests.
https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i

Market goes down. Time to Diversity to this stock.

In recent weeks since market has touched levels that, said that are the low point of the current bear market, there’s been a change in leadership among best performing sectors.com

For most of the first half of 2022, the only sector posting gains was energy, with utilities living up to their defensive reputation and posting the smallest losses among the 10 remaining sectors.

But since June 16, technology and consumer cyclical stocks are the leading sectors after being hit harder than the rest of the market in the first half of the year. Stocks leading the bounce include Amazon (AMZN), Tesla (TSLA), Home Depot (HD), and McDonald’s (MCD).

But watchfull eyes are looking out on whether it is just a relief rally or a more durable trend.

Good investors should not time the market, but to adapt and rotate based on the market sentiment and trend. Defensive stocks are a recommendation for all cautious investors ie. Healthcare, Utility, F&B and REITS.

A small cap healthcare industry which has not yet reach mainstream media is Regencell Bioscience Holding (RGC).

RGC is an early bioscience healthcare company which focuses on R&D and commercialsation treatment of ASD, ADHD and COV19 using Traditional Chinese Medicine (”TCM”) method.

Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.

Some highlights about the company executives and founders, showing long term conviction in the company:

- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.

This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targetting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.

[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)

Companies Working On Long Covid

There are a number of small companies are working on long Covid treatments.

More than four in survey of 10 people said that they knew someone with long Covid, a condition where symptoms persist for several weeks or longer. (Personally, 3 people i knew got covid in the same week out of the blue)

Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of **[ongoing health problems](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html)** that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.

But so far, large companies are shying away from treating the condition.

Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.

Hong Kong-based **Regencell Bioscience** is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.

The company’s formula aims to treat the core causes of disorders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s holistic approach toward the treatment process while preparing the TCM formulae for its patients.

[https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/](https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/)

Economist has voiced our concerns “Fed will push us into recession”

Economists have been raising their doubts in the FED’s capability in handling the rising inflation rate which is looking to fall of the edge into a oblivion recession.

As shared by economist Mohamed A. El-Erian “It is, unfortunately, uncomfortably possible that the Fed is going to slam on the brakes and push us into recession,” during his interview on Yahoo Finance Live in an online interview.

El-Erian’s also remarks that the Fed’s move last week in raising interest rates by 75 basis points (the most aggressive hike in decades) has made Wall Street strategist in notion for an economic slowdown.

The US Central bank was too late in acknowledging that inflation will become a problem and was not quick enough to reacting to the surging prices thus losing credibility in the eyes of wall street and also investors.

Losing credibility in the FED will lead to people doubting its projects, consequently leaving the people with skepticism and distrust towards the FED.

[https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html](https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html)

Investors are suggested to rotate their portfolio into defensive sectors which are known to be resilient towards times of economic recession ie. Healthcare, F&B, Utilities and REITs.

Regencell Bioscience Holdings , ticker $RGC is a bioscience healthcare company which had been listed in the NASDAQ market in USA. The company’s business is predominantly in the Research & Development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of the coronavirus disease esp. COVID-19, for which there are unmet holistic medical needs in the global market.

Since its inception into IPO last year July, the stock has seen a 300% rise. The stock has a Outstanding Shares of 13.01M and Floating Shares of 1.44M. The CEO is currently holding >80% of the company shares.

Defensive Healthcare - Potential to Hedge against Volatility.

The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.

The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.

Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.

The company's CEO (Mr. Yat-Gai Au, TCM Practitioner), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.


[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]

TCM’s Effectiveness to Treating COVID19 #RGC

Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which shook the world back in 2020.

Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC.

At present, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.

Mr Au, the company’s CEO and chairman has mentioned “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."

Aside from the company’s positive progress in medical, the CEO (Mr Au) has shown his confidence in the progress of the company direction and not sold a single share since taking his company to Initial Public Offering (”IPO”) in Year 2020. Mr Au has pledged to not take salary and bonus (<1$) until the company reaches US$1 Billion market cap as his target.

Presently, the company’s business plan of expansion is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.

https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html

The philanthropist behind Regencell Bioscience $RGC

Mr. *Yat-Gai Au* is the founder and CEO of Regencell. He graduated with a bachelor’s degree from UC Berkeley’s Haas School of Business and began his career in investment banking at Deutsche Bank and ING Barings.

Some of his accomplishments in his banking career were completed over US$4 billion worth of deals and won many prestigious M&A awards. Notable deals include the US$750 million acquisition of Philippine Long Distance Telephone, the US$650 million acquisition of Indofood and the US$1.8 billion secondary placement for 40% interest in Hagemeyer, all of which were executed on behalf of First Pacific Company Limited. He is also a founding partner of one of California’s largest group of property investors and an active technology and biotech investor.

Over the years, Yat-Gai has personally seen the amazing recovery of many ADHD and ASD patients using a particular Traditional Chinese Medicine treatment.

He established Regencell in 2015, after witnessing notable improvements in many cases, including close family members who had shown ADHD and ASD symptoms. Yat-Gai is now dedicating his professional efforts and personal funds to bringing the natural formula to patients, families and caregivers around the globe.

Mr Au personnel involvement in his own philanthropic project aims to provide care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties.

As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.

Yat-Gai is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged in Hong Kong and USA. During the 2020 COVID19 outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au setup Regencell Foundation Limited to further his charitable endeavors

[https://www.topionetworks.com/people/yat-gai-au-60866c12843bac2b60498b52]

$RGC ’s four-year lookout

RGC a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD and ASD, and infectious diseases targeting people’s immune system ie. COVID.

Mr Yat-Gai Au, a practitioner of TCM and also company CEO, since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.

***Upcoming results in follow-on study of ASD/ADHD treatment formula***

Regencell Bioscience is expected to report results of a follow-on study for its ASD/ADHD treatment. Currently, the Company is working towards the production of an effective standardized formula for commercialization purposes.

The formula is based on the “Sik-Kee Au TCM Brain Theory” that ASD and ADHD stem from inadequate blood flow and creation of neurotransmitters in the developing brain.

This treatment hypothesis is complementary to the western medicine view that ASD and ADHD are present at birth and arise from developmental differences in brain function.

Regencell Bioscience’s first clinical trial was designed to establish benchmarks for treatment, dosing, adverse effects (AEs) and measuring patients’ response in a systematic and repeatable way, while evaluating the effectiveness of a customized TCM formula.

As a customized formula is designed to suit each patient’s symptoms, the ability for it to be produced in large quantities is limited as compared to a standardized formula.

Regencell is currently evaluating and assessing the effectiveness of a standardized TCM formula in reducing ADHD and ASD symptoms in children through a holistic approach within 3 months of treatment, in its second efficacy trial.

**RGC’s Path to registration and commercialization**

Regencell Bioscience has a **four-year timeframe** to commercialize its standardized formulations and gain proprietary Chinese medicine (pCm) registration in Hong Kong. The Company has a number of tasks ahead:

- Completing its second clinical trial for ASD/ADHD and COVID, and evaluating results.
- Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.
- Obtaining patents and other forms of IP protection in Hong Kong and other markets.
- Establishing manufacturing capability and supply chain that will meet registration requirements.
- Assembling and filing documentation for pCm approval.
- Build out its marketing and distribution strategy and infrastructure.

#RGC Live on SSN Network - Results of TCM’s Effectiveness to Treating COVID19

Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which shook the world back in 2020.

Regencell Bioscience Holdings (RGC: Nasdaq) is a an early-staged bioscience healthcare company focusing on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

In latest findings, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.

An interview was held onf SSN Network (The Official Small-, Micro- and Nano-Cap News Source™) which included Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director; where they talk about the company, the procedures and protocols of their treatments and result findings.

[https://finance.yahoo.com/news/regencell-describes-traditional-chinese-medicine-133000084.html]

Separately, while Mr Au, the company’s CEO and chairman was not included as part of the interview, he has been working in in the background in defending his company from the recent short seller and trader attacks on the company stock. Mr Au has bought back over $5 Million Dollars of company share since taking the company IPO.

Mr Au has mentioned “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."

Aside from the company’s positive progress in medical, the CEO (Mr Au) has shown his confidence in the progress of the company direction and not sold a single share since taking his company to Initial Public Offering (”IPO”) in Year 2020. Mr Au has pledged to not take salary and bonus (<1$) until the company reaches US$1 Billion market cap as his target.

CEO's Defending and Pledging to Bring the Company Up

Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.

The company’s formula aims to treat the core causes of disorders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s holistic approach toward the treatment process while preparing the TCM formulae for its patients.

In order to approach the public with a transparent front, RGC’s CEO has decided to take a more approachable and honest form that is to well-align with shareholder’s long-term interests.

Taken from the CEO’s schedule 13D fillings with the SEC (US Security and Exchange Commission), the CEO has used an estimated amount of 5 million dollars of his personal funds to purchase ordinary shares via open market between July 21 and May 22’. This sums up a total of 10,539,159 ordinary shares owned by the CEO (Mr Au); representing ~81% of the company’s total issued and outstanding shares.

To gain further trust of fellow investors, Mr Au has pledge with the following points,

- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.

[https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html]

Mr Au is also been involved in his own philanthropic project (within his own means) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.

$RGC and IPO

The year 2021 has seen a huge number of 1,035 companies taking IPO in the US market; where the huge piece of the listings (35%) were in the biotech & healthcare sector.

Regencell Bioscience NASDAQ:[RGC] is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.

RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.

For year 2022, the company which shot to the moon since IPO is AMTD Digital NYSE:[HKD], a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.

Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.

Daily short volume (%) refers to the number of shares that have been shorted as compared to the total daily volume traded.

Comparison between the 2 companies can be found below article source;

[https://www.benzinga.com/amp/content/28316977]

TOP IPOs these 2 years!! #HKD #RGC

Some data on capital gains if you had gotten allocated shares during IPO for some of these top performing gains since their IPO in 2021.

Are there traders who mainly just bids for IPOs and take profit during opening bell or some hours/days after? Curious to know if plays like this are being practiced on a professional level.

Ranking,

1. Regencell Bioscience (RGC)
2. Diginal Worold Acquisition (DWC)
3. ZIM Integrated Shipping (ZIM)
4. Huadi International Group (HUDI)
5. Prometheus Bioscience (RXDX)
6. Apria (APR)
7. Mainz Biomed (MYNZ)

Must Have Stocks For Your Watchlist!

Company stocks are seen dropping to 2020 levels and it could be a considerable time for them to be greedy. (hooray to those who have spare cash to invest)

With multiple losses experienced by companies in recent quarter release, fears of a recession plague the market, the number of stocks considered undervalued breached levels seen at worst points of Covid-19 triggered recession

The U.S. market now trades at about a 15% discount, as overvalued stocks drop and stocks already trading at a bargain fall further into discount territory. As of July 19, the number stocks considered undervalued rose to 514, up from 289 at the end of the first quarter, an almost 78% increase.

A few companies to name are ,

1. Grupo Televisa (TV)
2. Infineon Technologies (IFNNY)
3. Regencell Bioscience (RGC)
4. Ingersoll Rand (IR)
5. Goldman Sachs (GS)

## **Grupo Televisa**

“We remain bullish on Televisa's long-term prospects. Historically a powerhouse in Spanish-language media because of its programming prowess and ownership of the leading broadcast networks in Mexico, the firm merged its media business into Univision. Televisa is now focused on telecom. The firm transformed itself into a leading telecom firm in Mexico through a series of acquisitions and is now one of the country’s fastest-growing broadband providers.”

## **Infineon Technologies**

“Infineon is a leading broad-based European chipmaker, with substantial exposure to secular growth drivers in the industrial and automotive chip sectors. Infineon should emerge as a leading supplier for electric vehicles and active safety systems used in cars, with increasing exposure to car "infotainment" systems. However, like most chipmakers, Infineon's business remains highly cyclical as demand ebbs and flows in line with the health of its various end markets.”

## Regencell Bioscience Holding

“CEO has been pledging been a strong supporter and putting his personnel funds in depending the company from short traders and hedge funds. The CEO has also pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization and will not award share options for himself; Further more, all directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.”

## **Ingersoll Rand IR**

“On Feb. 29, 2020, Gardner Denver acquired former Ingersoll-Rand’s industrial business in a transformative Reverse Morris Trust transaction. The combined entity took on the Ingersoll-Rand name and stock ticker.

“Following the merger, new Ingersoll-Rand is a leading mission-critical flow creation and industrial technology company. The combined entity operates under two reportable segments: 1) industrial technologies and services; and 2) precision and science technologies, including Gardner Denver's medical business. The combined business will benefit from a more comprehensive portfolio of products and services. Ingersoll-Rand’s large installed base of equipment generates a relatively stable stream of aftermarket and service revenue, which accounts for roughly 36% of combined pro forma sales.”

## **Goldman Sachs**

“Goldman Sachs has made progress on the strategic plan that it laid out at the beginning of 2020 and set even more ambitious goals in 2022. The company is now targeting a medium-term return on tangible equity (ROTE) of 15% to 17% compared with a previous goal of over 14%. In addition to the ROTE target, management also set an expense ratio goal of about 60% and growth targets for its asset management and consumer banking businesses. While we’re not sure the company will hit all of those goals over the next three years, we forecast the company exceeding a 15% ROTE in the long run after its consumer business has reached a more profitable scale. Goldman Sachs’ trading business also remains a large swing factor, as it requires more capital and tends to have lower operating margins than the other business segments.”

[https://www.morningstar.com/articles/1103336/8-newly-undervalued-5-star-stocks]

Missed Company Earnings, Market goes down. Time to Diversity to this stock.

In recent weeks since market has touched levels that, said that are the low point of the current bear market, there’s been a change in leadership among best performing sectors.com

For most of the first half of 2022, the only sector posting gains was energy, with utilities living up to their defensive reputation and posting the smallest losses among the 10 remaining sectors.

But since June 16, technology and consumer cyclical stocks are the leading sectors after being hit harder than the rest of the market in the first half of the year. Stocks leading the bounce include Amazon (AMZN), Tesla (TSLA), Home Depot (HD), and McDonald’s (MCD).

But watchful eyes are looking out on whether it is just a relief rally or a more durable trend.

Good investors should not time the market, but to adapt and rotate based on the market sentiment and trend. Defensive stocks are a recommendation for all cautious investors ie. Healthcare, Utility, F&B and REITS.

A small cap healthcare industry which has not yet reach mainstream media is Regencell Bioscience Holding (RGC).

RGC is an early bioscience healthcare company which focuses on R&D and commercialization treatment of ASD, ADHD and COV19 using Traditional Chinese Medicine (”TCM”) method.

Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.

Some highlights about the company executives and founders, showing long term conviction in the company:

- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.

This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targeting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.

[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)

Undervalue Biotech Stocks

Although recession may be on everyone's mind, these undervalued biotech stocks to buy feature extraordinary relevance at a great price.

With fears of a global recession rising, it’s natural that investors have turned their back on growth-intensive names. However, this backdrop has also yielded compelling undervalued biotech stocks to buy. While very few sectors have been spared the damage stemming from soaring inflation, geopolitical instability and supply chain disruptions, the biological sciences arena offers long-term relevance.

Mainly, it doesn’t matter whether a recession is about to capsize our economy or not. Since humans remain vulnerable to various diseases and medical conditions, it’s imperative that researchers continue to move forward. Therefore, undervalued biotech stocks to buy command significant interest because at some point, they have the potential to rise substantially higher.

To be fair, the underlying sector is volatile. And many times, a company sheds basis points in the equities market for a reason — often not a good one. Still, if you have some spare funds for speculation, these undervalued stocks to buy could offer significant bang for your buck.

1. BioMarin Pharmaceutical (BMRN): With its stable balance sheet, BioMarin Pharmaceutical is well-equipped to focus on therapies for rare diseases.

2. Ionis Pharmaceuticals (IONS): One of the undervalued biotech stocks to buy with a very wide footprint, Ionis Pharmaceuticals provides a compelling case for investors.

3. Exelixis (EXEL): An advanced therapeutics firm for cancer treatment, Exelixis also enjoys a robust balance sheet, providing confidence to prospective shareholders.

4. Intuitive Surgical (ISRG): Specializing in minimally invasive surgery, Intuitive Surgical makes for one of the most intriguing undervalued biotech stocks to buy.

5. Regencell Bioscience (RGC): Focusing on treatment of ADHD, ASD and COV19 via Traditional Chinese Medicine (”TCM”) method. Stock under radar of short sellers and traders. Might be a great pick for short squeeze players.

6. Affimed (AFMD): Leveraging the body’s immune system to target and kill tumor cells, Affimed could be a great deal to pick up for speculators.

7. Vir Biotechnology (VIR): Featuring cutting-edge technologies to combat infectious diseases, the pandemic has brought much relevance to Vir Biotechnology.

8. CRISPR Therapeutics (CRSP): An exciting though controversial gene-editing firm, CRISPR Therapeutics may be one of the undervalued biotech stocks to buy for the bold contrarian.

(https://finance.yahoo.com/news/stock-market-news-live-updates-july-27-2022-113235652.html)

Shorted this company in the past. Made good sum.

Regencell Bioscience Limited’s (NASDAQ:RGC) is a bioscience *healthcare* company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.

The company has seen a good rise of over 300% since taking the company IPO in July 2021, and have seen on a roller coaster ride between euphoria and depression in the recent months.

Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).

As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.

(https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/)

Top Performing IPO for 2021 & 2022; $RGC

The year 2021 has seen a huge number of 1,035 companies taking IPO in the US market; where the huge piece of the listings (35%) were in the biotech & healthcare sector. (A possible move by companies to ride on the Covid / Healthcare wave; just thinking out loud).

The company which had the largest gains since IPO does not turn heads when mentioned nor is it a name you seen in ads on television or YouTube. But this company was in the sight of many hedge funds and traders for a while period.

Regencell Bioscience (NASDAQ:[RGC](https://www.benzinga.com/stock/RGC#NASDAQ)). RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.

[A June 2022 article]( https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i) mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.

For year 2022, the company which shot to the moon since IPO is AMTD Digital (NYSE:[HKD]) (https://www.benzinga.com/stock/HKD#NYSE)), a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.

Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.

Comparison between the 2 companies can be found in the article link shard at the end of page.

(https://www.benzinga.com/amp/content/28316977)

Possible Short squeeze Play on Healthcare Counter #RGC

Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.

Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).

As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.

[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]

Latest short volumes taken from https://fintel.io/ss/us/rgc#](https://fintel.io/ss/us/rgc#

Regencell (RGC) was top performing IPO Stock in 2021 with 237% return above its IPO price of $9.50

The year 2021 was the busiest year for deals since 2000, with over a thousand (1035 nos) listed companies in the United States. Biotech and Healthcare sectors took an overwhelming portion of 36% of the total IPO listed.

While it is not the strategy for most investors to target IPO shares, it is a surprise that the top performing IPO counter is a company with does not turn heads when mentioned. (ie. not a household name or famous company).

Regencell Bioscience (NASDAQ:RGC). RGC is the top performing stock of all 2021 IPOs according to [stockanalysis.com/ipos/2021/](http://stockanalysis.com/ipos/2021/). As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.

An article published in June 2022 has covered that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.

Some key foundation points from the company,
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.

His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.

(https://www.benzinga.com/amp/content/28316977)